T. Kim

Phase 1b dose expansion and translational analyses of olaparib in combination with the oral AKT inhibitor capivasertib in recurrent endometrial, triple negative breast, and ovarian, primary peritoneal, or fallopian tube cancer

G. Mills, A. Jazaeri, R. Coleman, 2021, medRxiv.

Spitzoid melanoma with histopathological features of ALK gene rearrangement exhibiting ALK copy number gain: a novel mechanism of ALK activation in spitzoid neoplasia

J. Wargo, M. Tetzlaff, P. Nagarajan, 2018, The British journal of dermatology.